Viewing Study NCT03690856


Ignite Creation Date: 2025-12-24 @ 11:15 PM
Ignite Modification Date: 2026-02-24 @ 8:27 AM
Study NCT ID: NCT03690856
Status: UNKNOWN
Last Update Posted: 2021-02-03
First Post: 2018-09-18
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Clinical and Neurobiological Profile Predictive of Pejorative Outcome of Depression
Sponsor: Rennes University Hospital
Organization:

Study Overview

Official Title: DEPREDICT: Clinical and Neurobiological Profile Predictive of Pejorative Outcome of Depression
Status: UNKNOWN
Status Verified Date: 2021-02
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: DEPREDICT
Brief Summary: Depression is a frequent disease which can be marked by therapeutic resistance. It is described as one of the most disabling disease with high cost for society. World Health Organization pointed out that 350 million people are suffering from depression in the world. This pathology is considered underdiagnosed, with inadequate care resources and stigmatization.

There is a wide range of evidence in current literature that anxiety is one of the most important factors involved in biological mechanism of treatment resistance in depression. To date, there is a lack of knowledge on this topic. A better understanding of the role of anxiety in the maintenance of depressive state will allow to i) identify quickly and more accurately patients at risk of pejorative evolution and ii) develop specific therapeutics targeting this dimension which remain badly controlled with actual therapeutics.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: